T
Tatsuo Kagimura
Researcher at Foundation for Biomedical Research
Publications - 70
Citations - 993
Tatsuo Kagimura is an academic researcher from Foundation for Biomedical Research. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 14, co-authored 55 publications receiving 732 citations. Previous affiliations of Tatsuo Kagimura include Boehringer Ingelheim & International University of Health and Welfare.
Papers
More filters
Journal ArticleDOI
Utility of the REM sleep behavior disorder screening questionnaire (RBDSQ) in Parkinson’s disease patients
TL;DR: RBDSQ could be a useful tool for the screening of RBD in PD patients and a receiver-operator characteristics curve revealed that a total score of 6 points on the RBDSQ represented the best cut-off value for detecting RBD.
Journal ArticleDOI
Clinical significance of REM sleep behavior disorder in Parkinson's disease.
TL;DR: Clinical RBD symptoms, but not subclinical RBD, were associated with the development of dementia in patients with Parkinson's disease.
Journal ArticleDOI
Relationship between napping pattern and nocturnal sleep among Japanese nursery school children
Yoko Komada,Shoichi Asaoka,Takashi Abe,Noriko Matsuura,Tatsuo Kagimura,Shuichiro Shirakawa,Yuichi Inoue +6 more
TL;DR: Daytime naps naturally become less common after the third birthday among Japanese nursery school children and the longer the nap durations in 2- to 5-year-old children, the later they went to bed on the corresponding night.
Journal ArticleDOI
Reduction in High-Sensitivity C-Reactive Protein Levels in Patients with Ischemic Stroke by Statin Treatment: Hs-CRP Sub-Study in J-STARS.
Kazuo Kitagawa,Naohisa Hosomi,Yoji Nagai,Tatsuo Kagimura,Toshiho Ohtsuki,Hideki Origasa,Kazuo Minematsu,Shinichiro Uchiyama,Masakazu Nakamura,Masayasu Matsumoto +9 more
TL;DR: In non-cardiogenic ischemic stroke, pravastatin treatment may reduce vascular inflammation as assessed by Hs-CRP, and higher Hs -CRP levels appeared to increase the risk of recurrent stroke and vascular events.
Journal ArticleDOI
Long-term open-label study of pramipexole in patients with primary restless legs syndrome
TL;DR: Pramipexole showed good efficacy, particularly in patients with an IRLS total score <20, and adverse events were typical of nonergot dopamine agonists, mild in intensity, and decreased in frequency as the study progressed.